Variant-Specific IgA Protects Against Omicron Infection
The Journal of Infectious Diseases · 16.08.2024 · 230 (2) · e287-e291
DOI: 10.1093/infdis/jiad525 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 23.11.2023. Verfasst von Yun Shan Goh und 28 weiteren Autor:innen. Beteiligte Einrichtung: A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research, Singapore, Singapore. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, Immunoglobulin A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biomedical Research, Council, Agency for Science, Technology and Research.
Abstract (Originalsprache)
Background
The emergence of rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, coupled with waning vaccine-induced immunity, has contributed to the rise of vaccine breakthrough infections. It is crucial to understand how vaccine-induced protection is mediated.
Methods
We examined 2 prospective cohorts of mRNA vaccinated and boosted individuals during the Omicron wave of infection in Singapore.
Results
We found that individuals who remain uninfected over the follow-up period had a higher variant-specific IgA, but not IgG, antibody response at 1 month after booster vaccination, compared with individuals who became infected.
Conclusions
We conclude that IgA may have a potential contributory role in protection against Omicron infection. Clinical Trials Registration . NCT05142319.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research, Singapore, Singapore.
- Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.
- Bioinformatics Institute, Agency for Science, Technology and Research, Singapore, Singapore.
- GISAID Global Data Science Initiative, Munich, Germany.
- National Centre for Infectious Diseases, Singapore, Singapore.
- Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
ORCID-Profile: Xuan Ying Poh, Sebastian Maurer-Stroh, David C Lye, Laurent Renia
Förderung
- Biomedical Research
- Council
- Agency for Science, Technology and Research
- National Medical Research Council
- Singapore
- US Food and Drug Administration
- TF IPC, Ltd
- Nanyang Technological University
Zitieren
APA
Goh, Y. S., Fong, S. W., Hor, P. X., Loh, C. Y., Wang, B., Salleh, S. N. M., Ngoh, E. Z. X., Lee, R. T. C., Poh, X. Y., Rao, S., Chia, P. Y., Ong, S. W. X., Lee, T. H., Lim, C., Teo, J., Pada, S., Sun, L. J., Ong, D. L. S., Somani, J., …, & COVID-19 Cohort Study Group (2024). Variant-Specific IgA Protects Against Omicron Infection. The Journal of Infectious Diseases, 230(2), e287-e291. https://doi.org/10.1093/infdis/jiad525
Vancouver
Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, et al. Variant-Specific IgA Protects Against Omicron Infection. The Journal of Infectious Diseases. 2024;230(2):e287-e291. doi:10.1093/infdis/jiad525
BibTeX
@article{Goh2024,
author = {Goh, Yun Shan and Fong, Siew-Wai and Hor, Pei Xiang and Loh, Chiew Yee and Wang, Bei and Salleh, Siti Nazihah Mohd and Ngoh, Eve Zi Xian and Lee, Raphael Tze Chuen and Poh, Xuan Ying and Rao, Suma and Chia, Po Ying and Ong, Sean W X and Lee, Tau Hong and Lim, Clarissa and Teo, Jefanie and Pada, Surinder and Sun, Louisa Jin and Ong, Desmond Luan Seng and Somani, Jyoti and Lee, Eng Sing and Maurer-Stroh, Sebastian and Wang, Cheng-I and Leo, Yee-Sin and Lye, David C and Young, Barnaby Edward and Ng, Lisa F P and Renia, Laurent and NCID Study Group, NCID Study Group and COVID-19 Cohort Study Group, COVID-19 Cohort Study Group},
title = {Variant-Specific IgA Protects Against Omicron Infection},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {2},
pages = {e287--e291},
doi = {10.1093/infdis/jiad525}
}
EUVIMED